Upcoming Events
Webinar: New Approaches to Personalize Endocrine Therapy in Early-Stage, HR+ Breast Cancer
The evolving role of the Breast Cancer Index® Test – the leading genomic assay for extended endocrine therapy decisions, with new data supporting expanded utility of the test (coming summer 2026):*
• Postmenopausal patients: Help individualize primary adjuvant endocrine therapy*
• Premenopausal patients: Help inform ovarian function suppression*
Speaker: Rena Callahan†, MD, University of California, Los Angeles
Webinar Dates:
March 5, 2026, 4:00 PM PST
March 11, 2026, 6:00 PM PST
March 18, 2026, 5:00 PM PST
†Speaker listed is a consultant of Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.
*Not currently available to order. The features and results of the Breast Cancer Index Test, to the extent they differ from the information found on the BreastCancerIndex.com website, including, but not limited to, the features concerning adjuvant endocrine therapy and ovarian function suppression: (i) are not currently available for clinical use; (ii) will be made available only after all required internal validations and regulatory requirements have been met; and (iii) is being provided herein for informational purposes only, and shall not be deemed to be an offer of availability.
Hologic Data Privacy Policy: https://www.hologic.com/privacy-policy
Hologic Data Terms and Conditions: https://www.hologic.com/terms-conditions